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Abstract
Background: N-(6-(4-chlorophenoxy)hexyl)-N'-cyano-N''-4-pyridyl guanidine) (CHS 828) is the
first candidate drug from a novel group of anti-tumour agents – the pyridyl cyanoguanidines, shown
to be potent compounds interfering with cellular metabolism (inhibition of nicotinamide
phosphoribosyl transferase) and NF-κB signalling. Substituted cyanoguanidines are also found in
anti-hypertensive agents such as the potassium channel opener pinacidil (N-cyano-N'-(4-pyridyl)-
N''-(1,2,2-trimethylpropyl)guanidine) and histamine-II receptor antagonists (e.g. cimetidine, N-
cyano-N'-methyl-N''-[2-[[(5-methylimidazol-4-yl]methyl]thio]ethyl)guanidine). In animal studies,
CHS 828 has shown very promising activity, and phase I and II studies resulted in further
development of a with a water soluble prodrug.
Findings:  To study the structural requirements for cyanoguanidine cytotoxicity a set of 19
analogues were synthesized. The cytotoxic effects were then studied in ten cell lines selected for
different origins and mechanisms of resistance, using the fluorometric microculture cytotoxicity
assay (FMCA). The compounds showed varying cytotoxic activity even though the dose-response
curves for some analogues were very shallow. Pinacidil and cimetidine were found to be non-toxic
in all ten cell lines. Starting with cyanoguanidine as the crucial core it was shown that 4-pyridyl
substitution was more efficient than was 3-pyridyl substitution. The 4-pyridyl cyanoguanidine
moiety should be linked by an alkyl chain, optimally a hexyl, heptyl or octyl chain, to a bulky end
group. The exact composition of this end group did not seem to be of crucial importance; when
the end group was a mono-substituted phenyl ring it was shown that the preferred position was 4-
substitution, followed by 3- and, finally, 2-substitution as the least active. Whether the substituent
was a chloro, nitro or methoxy substituent seemed to be of minor importance. Finally, the activity
patterns in the ten cell lines were compared. Substances with similar structures correlated well,
whilst substances with large differences in molecular structure demonstrated lower correlation
coefficients.
Conclusion: According to this structure-activity relationship (SAR) study, CHS 828 meets the
requirements for optimal cytotoxic activity for this class of compounds.
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Background
The anti-tumoral activity of the pyridyl cyanoguanidines
was first detected in a routine in vivo screening programme
in a rat model with Yoshida ascites sarcoma cell tumours.
The studied compounds were synthesized as analogues to
the anti-hypertensive potassium channel opener pinacidil
(Fig. 1). Replacement of the side chain by longer aryl-con-
taining side chains caused a loss of activity in this respect,
and a candidate drug, N-(6-(4-chlorophenoxy)hexyl)-N'-
cyano-N''-4-pyridyl guanidine) (CHS 828), was selected
after studies of structure-activity relationships (SARs) in
vitro and preliminary evaluation in vivo [1].
Cyanoguanidines hyperpolarizing adenosine triphos-
phate (ATP)-sensitive potassium channels in the smooth
muscle of the bladder have received attention as drug can-
didates for overactive bladder. One example is shown in
Figure 1[2]. In addition to their appearance in pinacidil
and other potassium channel openers (on which CHS 828
has no activity), substituted cyanoguanidines are also
found in histamine-II receptor antagonists (e.g. cimeti-
dine, N-cyano-N'-methyl-N''-[2-[[(5-methylimidazol-4-
yl]methyl]thio]ethyl)guanidine) (Fig. 1).
As CHS 828 displays a broad spectrum of activity, low
cross-resistance with standard drugs, favourable in vitro
therapeutic indices [1,3,4] and IC50 values in the nano-
molar range, the drug was brought into phase I clinical tri-
als [5,6]. A detailed description of the mechanism of
action of CHS 828 was not presented until 2004 when Dr
Stangelshøj Olsen and co-workers published data sup-
porting inhibition of the Inhibitory κ-B kinase (IKK) com-
plex, with an IC50 of 8 nM [7]. The mechanism of action
may, however, be dual, and may in part depend on drug
concentration and exposure time as suggested by Hassan
et al [8]. According to Ekelund et al [9], high concentra-
tions (1 and 10 μM, well exceeding the IC50) of CHS 828,
just like meta-iodobenzyl guanidine (MIBG), inhibit
mitochondrial respiration, with a subsequent increase in
glycolysis to cover the energy need. Interestingly, this high
concentration effect is similar in resistant U-937/CHS
cells and the U-937 GTB cells [9]. In addition, it was
shown that cells grown in pyruvate-supplemented, glu-
cose-free medium are, at least partly, protected from CHS
828 toxicity, thereby indicating that the extent of glycoly-
sis may be an important determinant of optimal CHS 828
activity [9]. The process following CHS 828 exposure is
characterized by an almost normal proliferation during
the first 24 hours followed by an abrupt shut-off of deox-
yribonucleic acid (DNA) and protein synthesis, a modest
increase in caspase-3 activity and DNA fragmentation,
and the first signs of cell death [10,11]. These processes
seem dependent on intact protein synthesis [10]. Addi-
tion of the adenosine diphosphate (ADP) ribosylation
inhibitor 3-aminobenzamide to the medium and U-937
cells exposed to CHS 828 resulted in a 100-fold decrease
in IC50, and also in more predominant apoptotic cell
death [12]. This effect, however, appears to be unrelated
to the effects on poly(ADP-ribose) polymerase (PARP),
and the authors suggest that it is mediated through effects
on glycolytic enzymes, such as glyceraldehyde-3-phos-
phate [12]. In the subsequent paper it was shown that
Substituted cyanoguanidines with defined pharmacological effects Figure 1
Substituted cyanoguanidines with defined pharmacological effects: A Cytotoxic CHS 828; B Potassium channel 
openers pinacidil (B1) and 12 g of compound as described in Perez-Medrano et al [2] (B2); and C Histamine-II receptor antag-
onist cimetidine.
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PARP-1 inactivation in mouse fibroblasts in fact sensitizes
cells to the cytotoxic action of CHS 828, and conse-
quently, that the drug is able to activate different cellular
pathways depending on PARP status [13]. During the
2007 American Association for Cancer Research/National
Cancer Institute/European Organization for Research and
Treatment of Cancer (AACR-NCI-EORTC) International
Conference on Molecular Targets and Cancer Therapeu-
tics, Roulston and co-workers at Gemin X Biotechnologies
Inc. presented data strongly suggesting that GMX1778
(EB1627), a soluble prodrug of CHS 828, acts by inhibi-
tion of nicotinamide phosphoribosyl transferase
(Nampt), an enzyme involved in nicotinamide adenine
dinucleotide (oxidized) (NAD+) biosynthesis, and that
nuclear factor-kappa B (NF-κB) inhibition is only a conse-
quence of NAD+ decline [14]. This mechanism was
recently confirmed in a study by Dr Høgh Olesen and co-
workers, including cross-resistance to FK866, a known
inhibitor of Nampt [15]. Nampt has also been presumed
to be a cytokine (PBEF) or a hormone (visfatin). The crys-
tal structure of Nampt in the presence and absence of
nicotineamide mononucleotide shows that Nampt is a
dimeric type II phosphoribosyltransferase and provides
insights into the enzymatic mechanism [16]. Previously
noted effects by CHS 828 on glycolysis and inhibition of
the transcription factor NF-κB can likely be secondary to
inhibition of Nampt.
The aim of this study was to establish the structural
requirements for cyanoguanidine cytotoxicity. The cyto-
toxic effects of nineteen substituted pyridyl cyanoguani-
dines, with variations in pyridyl substitution, different
alkyl chain linkers and end groups, were studied on a
panel of ten cell lines.
Methods
Cell lines
Cytotoxicity was assayed in a panel of ten human tumour
cell lines. This panel was previously established for use in
the early investigation of new anti-cancer compounds,
and the cell lines represent different histological origins
and mechanisms of resistance [17]. The panel has success-
fully been used in in vitro evaluation of a wide range of dif-
ferent cytotoxic agents, both for clinical and for
investigational purposes. A brief description of the cell
lines is presented in Table 1. Cells were maintained as pre-
viously described [17].
Medium and reagents
Cell growth medium RPMI-1640 (Sigma Chemical Co.,
St. Louis, MO, USA) supplemented with 10% heat-inacti-
vated foetal calf serum (FCS) (Sigma), 2 mM glutamine,
100 μg/mL streptomycin and 100 U/mL penicillin was
used for all experiments. Fluorescein diacetate (FDA)
(Sigma) was dissolved in dimethylsulphoxide (DMSO)
(Sigma) to a concentration of 10 mg/mL and kept frozen
as a stock solution in the dark.
Test compounds
The test compounds, a set of 19 structure analogues to
CHS 828 with the cyanoguanidine core preserved, was a
kind gift from the Department of Chemical Research, Leo
Pharma, Ballerup, Denmark. Compounds were synthe-
sized using methods described elsewhere [1,9].
Cytotoxicity assay
The FMCA has been previously described in detail [18-
20]. The method is based on 72-hour drug exposure in 96-
well microtitre plates, whereafter cells are washed and the
fluorescence generated from hydrolysis of fluorescein dia-
cetate is measured. Fluorescence is proportional to the
number of living cells in the well. The method has been
used extensively for experimental as well as clinical pur-
poses, and seems valuable with most classes of chemo-
therapeutic drugs. For concentration-response curves,
each drug was tested at five different concentrations, each
concentration in triplicate. Each 96-well microtitre plate
had six control (unexposed cells) and six blank (cell
medium only) wells. Quality criteria for a successful assay
included > 90% starting viability (judged by Trypan blue
exclusion), a control signal more than ten times the blank,
and, finally, a coefficient of variation in control and blank
wells of < 30%.
Statistical analysis
Direct comparisons of the activity for the substances were
made by using paired t-tests in GraphPad Prism, version 4
(Graphpad Software Inc., La Jolla, CA, USA).
Table 1: Cell line characteristics
Parental cell line Sub-line(s) Origin Selecting agent Proposed resistance mechanism
CCRF-CEM CEM/VM-1 Leukaemia Teniposide Topo II-associated
NCI-H69 H69/AR SCLC Doxorubicin MRP
RPMI8226/S 8226/Dox40 Myeloma Doxorubicin Pgp
8226/LR5 Melphalan GSH
U-937 GTB U-937 Vcr Lymphoma Vincristin Tubulin-associated
ACHN - Renal Primary resistant
GSH = glutathione; Pgp = p-glycoprotein 170; SCLC = small-cell lung cancer; Topo II = topo-isomerase II MRP = Multidrug resistance associated 
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Results
The compounds showed varying cytotoxic activity allow-
ing the SAR analysis; however, the dose-response curves
for some analogues were very shallow, in several cases
ending in a plateau at a survival index of 20–80%, thereby
preventing a correct determination of the IC50 value. This
characteristic dose-response profile has been previously
described for CHS 828 in the fluorometric microculture
cytotoxicity assay (FMCA) [3]. Prolonged assay time (vio-
lation to standard FMCA protocol) to 144 hours produced
better dose-response curves and allowed determination of
the IC50 values, results were similar but slightly changed
(not shown). To avoid interference the survival index at
10 μM (on the plateau) was used with FMCA assay time
72 hrs (standard protocol). In a phase I trial reported by
Ravaud et al [5] CHS 828 was given orally as a singe dose
every 3 weeks. Doses up to 500 mg was given, which
resulted in plasma concentrations of 11 μM. The inherent
order of sensitivity among the cell lines was similar to that
presented previously [3], with the doxorubicin resistant
small-cell lung cancer (SCLC) cell line H69AR being the
most sensitive and the maternal myeloma cell line RPMI
8226S being highly sensitive, while the doxorubicin-
selected (p-glycoprotein (Pgp)-expressing) sub-line, 8226
Dox40, displayed a considerable degree of resistance, as
did the T-cell leukaemia lines CCRF-CEM and CEM/R.
This pattern of activity among the cell lines was similar for
most of the compounds (see below). The reference com-
pounds pinacidil and cimetidine (Fig. 1) were tested in
concentrations of up to 10 mM in all ten cell lines and
were found to be non-toxic (not shown).
First, the pyridyl substitution pattern on the cyanoguani-
dine core was studied. As seen in Figure 2, 4-pyridyl sub-
stitution was significantly more efficient than was 3-
pyridyl substitution (p < 0.01).
Second, the linking alkyl chain length was examined. This
factor was apparently of considerable importance, having
optimum activity with hexyl, heptyl or octyl chains end-
ing with a bulky end group (Fig. 3). The exact composi-
tion of this end group did not seem to be of crucial
importance (Fig. 4A). When the end group was a mono-
substituted phenyl ring it was shown that the preferred
position was 3-substitution, followed by 2- and, finally, 4-
substitution, but differences were minor. The compound
with an unsubstituted phenyl was as active as the 4-substi-
tuted compounds, while the trichlorinated derivative
appeared less active (however, the difference was statisti-
cally not significant; p = 0.13). Whether the substituent(s)
was a chloro- or methoxy-group(s) seemed to be of minor
importance (Fig. 4B).
Finally, the activity patterns in the ten cell lines were com-
pared. Substances with similar structures correlated well,
whilst substances with large differences in molecular
structure demonstrated lower correlation coefficients (not
shown).
Discussion
The unsubstituted pyridyl moiety appears important,
although it has not been studied in detail in the present
study. Others have shown that a substituted pyridyl or a phe-
Effects of pyridyl substitution pattern on cytotoxic activity (as  survival index at 10 μM) in the ten cell lines studied Figure 2
Effects of pyridyl substitution pattern on cytotoxic 
activity (as survival index at 10  M) in the ten cell 
lines studied. The symbols for each cell line is used in figure 
2–4.
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Effects of linking chain length on cytotoxic activity (as survival  index at 10 μM) in the cell lines studied Figure 3
Effects of linking chain length on cytotoxic activity 
(as survival index at 10  M) in the cell lines studied. 
Symbols as in figure 2.
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nyl substituent strongly reduces the cytotoxic activity of the
compounds. Interestingly, however, N-(6-(4-chlorophe-
noxy)hexyl)-N'-cyano-N''-((2-methoxy)-5-pyridyl guani-
dine is a fairly potent inhibitor of the IKK activity in vitro
(IC50 22 nM v. 8.0 nM for CHS 828), which contrasts with its
low anti-proliferative activity against NYH SCLC cells in vitro
and in vivo [7], and consequently in this particular case the
cytotoxic action and the IKK inhibitory action appear sepa-
rate. Furthermore, while retaining the capacity of increasing
the glycolytic activity in U-937 cells, this compound appears
to be almost atoxic also in this cell line (compound 8 in Eke-
lund et al [9]), again leading to speculations about a dual
mechanism of action. Compounds with the pyridyl ring sub-
stituted for a mono or unsubstituted phenyl ring display no
IKK inhibitory or cytotoxic activity [7]. Arylcyanoguanidines
with short aliphatic side chains (e.g. N-aryl-N'-cyano-N''-
alkyl-guanidines) are known as activators of ATP-sensitive
potassium channels and inhibitors of insulin release from
beta cells, but small structural changes can dramatically
change the efficacy [21].
The length of the alkyl chain linking the cyanoguanidine
to a bulky end group proved to be important, ideally
being an hexyl to an octyl chain, in agreement with a pre-
vious report from Schou and co-workers [1]. In light of
this, it is worth noting that the dodecyl derivative with a
tert-butyloxycarbonylamino end group (CHS 850) never-
theless has shown high potency as an inhibitor of IKK
activity, as well as proliferation of NYH SCLC cells in vitro
and in vivo [7].
It has recently been shown that different Na+/H+ exchange
inhibitors, including the cyanoguanidine cimetidine, also
inhibit chemokine production and NF-κB activation in
immuno-stimulated endothelial cells [22]. For the model
substance in these studies, amiloride (with no structural
relationship to the cyanoguanidines), this was suggested
to result from an inhibitory effect on IκB degradation
[22]. Cimetidine and amiloride are both completely non-
toxic in the FMCA model in the cell lines studied (Ekelund
et al [23] and unpublished data), and interaction analysis
between amiloride and CHS 828 in U-937 cells has shown
synergistic effects [23].
In order to develop a second-generation drug candidate
from CHS 828 with the aim to improve cytotoxicity and/
or selectivity, Chern and co-workers synthesized ana-
logues with a bridge connecting the two amino nitrogens
of the cyanoguanidine, thus forming a cyclic structure
such as 2-cyanoimino-4-imidazodinone derivatives.
Some of these drugs, especially the 5-substituted ones,
displayed cytotoxic activities at sub-micromolar level.
However, in contrast to the analogue series presented in
this paper, the rigid analogues appeared to display a dif-
ferent activity spectrum compared with the model com-
pound (namely, higher activity against colon and liver
cancer cell lines, and lower activity against gastric,
nasopharyngeal and breast cancer) [24]. However, it is at
present unclear whether these compounds with cyclic
structures displays a more favourable activity profile than
the compounds described in our work.
Effects of different end groups (4A); and end group substituents (4B), on cytotoxic activity (as survival index at 10 μM) in the  cell lines studied Figure 4
Effects of different end groups (4A); and end group substituents (4B), on cytotoxic activity (as survival index at 
10  M) in the cell lines studied. Symbols as in figure 2.
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Conclusion
The cytotoxic cyanoguanidines, with CHS 828 as the
model compound, have received a fair amount of atten-
tion in the scientific literature, and early clinical trials have
been performed. Further development resulted in a water
soluble prodrug called EB1627 (also denoted GMX1777).
Prolonged infusions of EB1627 have recently been
reported to yield significant effects in myeloma, small cell
lung cancer and colon cancer xenografts, which according
to the authors support the design of an open-label, dose-
escalation trial, in which patients with refractory solid
tumors and lymphomas receive 24 h infusions of EB1627
as a single agent in 3-week cycles. Furthermore, results
indicate that nicotinic acid is a potent antidote to treat
EB1627 overdose [25].
Despite efforts for 10 years to pinpoint details of the
mechanistic events following exposure to the drug, the
exact mechanism of action was not established until very
recently. Malignant cells display increased demands for
energy production and DNA repair, and NAD is required
for both processes and is also continuously degraded by
cellular enzymes. N-(6-(4-chlorophenoxy)hexyl)-N'-
cyano-N''-4-pyridyl guanidine most probably acts by inhi-
bition of nicotinamide phosphoribosyltransferase
(Nampt), a crucial factor in the resynthesis of NAD
[14,15]. Using a functional non-clonogenic viability assay
we identified structural prerequisites for cytotoxicity, and
found CHS 828 to be a reasonable drug candidate.
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